



Financial Tear Sheet

Corporate Profile

Edge Therapeutics is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening conditions.

We believe **EG-1962**, our lead product candidate, can fundamentally improve patient outcomes and transform the management of aneurysmal subarachnoid hemorrhage, or aSAH, which is bleeding around the brain due to a ruptured brain aneurysm. A single dose of EG-1962 delivers a high concentration of nimodipine, the current standard of care, directly to the brain with sustained drug exposure over 21 days.

In April 2015, we completed enrollment in a Phase 1/2 trial of **EG-1962** in North America, which we refer to as our NEWTON trial, and met our primary and secondary endpoints of safety, tolerability, maximum tolerated dose (MTD) and pharmacokinetics. We intend to initiate our Phase 3 program in the first half of 2016.

Our second product candidate, EG-1964, is being developed as a potential prophylactic treatment in the management of chronic subdural hematoma, or cSDH, to prevent recurrent bleeding on the surface of the brain. Recurrent bleeding occurs in up to 30% of cSDH patients, requires repeat neurosurgical intervention and is associated with risks of serious complications, including death. There are currently no approved therapeutic treatments that reduce the risk of recurrent bleeding after cSDH. Following discussions with the FDA, we intend to submit an IND for EG-1964 in 2016.


Stock Performance

Primary IR Contact

Gregory Gin

E-mail:

ir@edgetherapeutics.com



EDGE (Common Stock)

Exchange NASDAQ GS (US Dollar)

Financial Status Indicator C

Price **\$1.21**

Change (%) ▲ 0.06 (5.22%)

Volume 120,145

52 Week Low \$0.95

Market Cap \$35,499,586

Rolling EPS -2.11

PE Ratio 0

Shares Outstanding 30,869,205

Data as of April 26, 2018 4:00 p.m. ET

Recent Press Releases & Upcoming Events

March 28, 2018

Edge Therapeutics Provides Update following Interim Analysis of Phase 3 NEWTON 2 Study of EG-1962 in Aneurysmal Subarachnoid Hemorrhage

March 1, 2018

Edge Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results

February 26, 2018

Edge Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results Conference Call on March 1, 2018

There are currently no events scheduled.

SEC Filings

Filing Date	Form
April 25, 2018	DEFA14A
April 25, 2018	DEF 14A
April 25, 2018	8-K
April 10, 2018	SC 13G/A

Corporate Governance

Brian Leuthner	President and CEO
R. Loch Macdonald, M.D., Ph.D	Chief Scientific Officer
Andrew Einhorn	Chief Financial Officer
Herbert J. Faleck, D.O.	Chief Medical Officer
Bert Marchio	Chief Accounting and Operations Officer
Alpaslan Yaman, Ph.D.	Vice President, Operations and Manufacturing
W. Bradford Middlekauff	Senior Vice President and General Counsel

Data provided by Nasdaq. Minimum 15 minutes delayed.